[Update on antibiotic therapy. 17) A combination of fosfomycin and cephalexin (cefemic cofosfolactamine)].
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001667:Binding, Competitive; D002506:Cephalexin / Q000378:metabolism / Q000627:therapeutic use*; D004338:Drug Combinations; D004357:Drug Synergism; D004358:Drug Therapy / Q000639:trends*; D004791:Enzyme Inhibitors; D004927:Escherichia coli Infections / Q000188:drug therapy; D005578:Fosfomycin / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy; D011512:Proteus Infections / Q000188:drug therapy; D012480:Salmonella Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D004791:Enzyme Inhibitors; D005578:Fosfomycin; D002506:Cephalexin
Aggiornamenti in terapia antibiotica. 17) Associazione fosfomicina-cefalessina (cofosfolattamina cefemica).